Domestically developed new drugs in the P-CAB (Potassium-competitive gastric acid secretion inhibitor) series are accelerating their overseas expansion. HK inno.N K-CAB and Daewoong Pharmaceutical Fexuclue both set a global sales goal of 1 trillion won within five years. To this end, K-CAB has obtained product approval in 7 countries. In addition, the company announced expansion into a total of 35 countries, including technology and finished product export contracts. Fexuclue also obtained product approvals in four countries and signed technology and finished product export contracts with a total of 15 countries. According to the pharmaceutical industry on the 19th, Daewoong Pharmaceutical recently received product a